🇺🇸 FDA

Intelligence · Clinical Pipeline

Oncology · Phase II

Oncology programs at Phase II — ClinicalTrials.gov pipeline intelligence.

Programs
2,640

Quick answer

Oncology Phase II programs: NovaPharmaNews indexes 2,640 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.

Top sponsors

Page 34 of 55

  1. Nimotuzumab

    The First People's Hospital of Lianyungang

    Esophageal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  2. Nimotuzumab

    Chinese University of Hong Kong

    Esophageal Cancer

    phase 2 small molecule completed

    1 trial

  3. Nimotuzumab

    The First People's Hospital of Lianyungang

    Esophageal Neoplasms

    phase 2 small molecule active

    1 trial

  4. Nimotuzumab + SHR-1210

    The First People's Hospital of Lianyungang

    Esophageal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  5. Nimotuzumab combined with chemoradiotherapy

    The First People's Hospital of Lianyungang

    Pancreatic Cancer Non-resectable

    phase 2 small molecule active

    1 trial

  6. Niraparib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Ovarian Cancer

    phase 2 small molecule active

    1 trial

  7. Niraparib

    Takeda

    Ovarian Cancer

    phase 2 small molecule completed

    2 trials

  8. Niraparib

    Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

    Platinum-resistant Recurrent Clear Cell Ovarian Cancer

    phase 2 small molecule completed

    1 trial

  9. Niraparib-Bevacizumab

    Takeda

    Platinum-sensitive Recurrent Ovarian Cancer Patients Previously Treated With a PARP Inhibitor

    phase 2 small molecule active

    1 trial

  10. Nivo 240 mg and Rela 80 mg per vial, OPDIVO 10 mg/mL concentrate for solution for infusion., Relatlimab

    Bristol-Myers Squibb Australia Pty Ltd

    Neoplasms by site

    phase 2 small molecule active

    1 trial

  11. Nivolumab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Advanced Biliary Tract Cancer(BTC)

    phase 2 small molecule active

    1 trial

  12. Nivolumab

    United Therapeutics Europe Ltd

    Metastatic Uveal Melanoma

    phase 2 small molecule completed

    1 trial

  13. Nivolumab

    Bristol-Myers Squibb

    Prostate Cancer

    phase 2 mab completed

    1 trial

  14. Nivolumab

    Bristol-Myers Squibb

    Hepatocellular Carcinoma

    phase 2 mab completed

    1 trial

  15. Nivolumab

    Mereo BioPharma Group plc

    Ovarian Cancer

    phase 2 small molecule active

    1 trial

  16. Nivolumab

    Adaptive Biotechnologies Corp

    Bladder Cancer

    phase 2 small molecule completed

    1 trial

  17. Nivolumab & Ipilimumab

    The First People's Hospital of Lianyungang

    Lung Cancer - Non Small Cell

    phase 2 small molecule active

    1 trial

  18. Nivolumab Injection [Opdivo]

    The First People's Hospital of Lianyungang

    Neoplasms

    phase 2 small molecule active

    1 trial

  19. Nivolumab Subcutaneous, BMS986482, FDC Nivolumab + Relatlimab + rHuPH20 Injection, BMS986482, BEVACIZUMAB

    Bristol-Myers Squibb Australia Pty Ltd

    Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

  20. OBINUTUZUMAB, Zanubrutinib

    BeiGene

    Relapsed/Refractory Follicular Lymphoma

    phase 2 small molecule active

    1 trial

  21. OGX-011

    United Therapeutics Europe Ltd

    Prostate Cancer

    phase 2 mab completed

    1 trial

  22. OLAPARIB, BEVACIZUMAB

    The George Institute

    Advanced FIGO Stage III‐IV High Grade Serous or Endometrioid Ovarian, Fallopian Tube, or Peritoneal Cancer

    phase 2 small molecule active

    1 trial

  23. OMEPRAZOLE , ACETYLSALICYLIC ACID

    The George Institute

    Colorectal cancer

    phase 2 small molecule active

    1 trial

  24. OMP-59R5

    Mereo BioPharma Group plc

    Stage IV Small Cell Lung Cancer

    phase 2 small molecule terminated

    1 trial

  25. OMP-59R5

    Mereo BioPharma Group plc

    Stage IV Pancreatic Cancer

    phase 2 small molecule completed

    1 trial

  26. ONDANSETRON , APREPITANT , PALONOSETRON, COMBINATIONS, PALONOSETRON , Lagipra, GRANISETRON , DEXAMETHASONE , 0.9% sodium chloride

    Eli Lilly Co.

    Nausea, Drug-Related Side Effects and Adverse Reactions, Vomiting, Neoplasms

    phase 2 small molecule active

    1 trial

  27. ONO-4578

    Ono Pharmaceutical Co.,

    Colorectal Cancer

    phase 2 small molecule active

    1 trial

  28. ONO-4578, ONO-4578, BEVACIZUMAB, ONO-4578, CALCIUM FOLINATE, OXALIPLATIN, OPDIVO 10 mg/mL concentrate for solution for infusion., FLUOROURACIL

    Lacuna Pharma Pty Ltd

    PD-L1 positive advanced colorectal cancer

    phase 2 small molecule active

    1 trial

  29. OP-1250

    Olema Pharmaceuticals

    Hormone Receptor Positive Breast Carcinoma

    phase 2 small molecule completed

    1 trial

  30. OPDIVO 10 mg/mL concentrate for solution for infusion.

    The George Institute

    Relapsing/Refractory ALK+ Anaplastic Large cell Lymphoma

    phase 2 small molecule active

    1 trial

  31. OPDIVO 10 mg/mL concentrate for solution for infusion.

    Ningbo Cancer Hospital

    Early stage triple negative breast cancer

    phase 2 small molecule active

    1 trial

  32. OPDIVO 10 mg/mL concentrate for solution for infusion., Anti-Fucosyl GM1 PET Tracer, ETOPOSIDE, CARBOPLATIN

    Bristol-Myers Squibb Australia Pty Ltd

    Extensive-stage Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  33. OPDIVO 10 mg/mL concentrate for solution for infusion., BDC-1001, OPDIVO 10 mg/mL concentrate for solution for infusion., OPDIVO 10 mg/mL concentrate for solution for infusion.

    Bolt Biotherapeutics

    Advanced HER2-Expressing Solid Tumors.

    phase 2 small molecule active

    1 trial

  34. OPDIVO 10 mg/mL concentrate for solution for infusion., FLUOROURACIL , Oxaliplatino Sandoz, LEDERFOLIN 175 mg polvere per soluzione per infusione, FLUOROURACIL , SIMVASTATIN, CAPECITABINE

    Fondazione Telethon ETS

    advanced or metastatic gastrooesophageal carcinoma HER2 negative and ARID1A mutated

    phase 2 small molecule active

    1 trial

  35. OPDIVO 10 mg/mL concentrate for solution for infusion., Ipilimumab, Ipilimumab

    Bristol-Myers Squibb Australia Pty Ltd

    Advanced or metastatic solid tumors: 1) Triple Negative Breast Cancer (TNBC) 2) Gastric Cancer (GC) 3) Pancreatic Cancer (PC) 4) Small Cell Lung Cancer (SCLC). 5) Bladder Cancer (BC) 6) Ovarian Cancer (OC)

    phase 2 small molecule active

    1 trial

  36. OPDIVO 10 mg/mL concentrate for solution for infusion., Ipilimumab, OPDIVO 10 mg/mL concentrate for solution for infusion., DARZALEX 20 mg/mL concentrate for solution for infusion, Relatlimab, Relatlimab

    Bristol-Myers Squibb Australia Pty Ltd

    MSI Negative Colorectal Cancer, MSI Positive Colorectal Cancer

    phase 2 small molecule active

    1 trial

  37. OPDIVO 10 mg/mL concentrate for solution for infusion., Kymriah 1.2 x 10^6 – 6 x 10^8 cells dispersion for infusion

    Pari Pharma GmbH

    children, adolescents and young adults with Acute Lymphoblastic Leukemia

    phase 2 small molecule active

    1 trial

  38. OPDIVO 10 mg/mL concentrate for solution for infusion., Mektovi 15 mg film-coated tablets, YERVOY 5 mg/ml concentrate for solution for infusion, YERVOY 5 mg/ml concentrate for solution for infusion, Braftovi 75 mg hard capsules

    Ningbo Cancer Hospital

    BRAF V600 mutation–positive unresectable or metastatic melanoma

    phase 2 small molecule active

    1 trial

  39. OPDIVO 10 mg/mL concentrate for solution for infusion., Regorafenib_IJB

    The George Institute

    Locally-advanced stage II-III rectal cancer

    phase 2 small molecule active

    1 trial

  40. OPDIVO 10 mg/mL concentrate for solution for infusion., Relatlimab intravenous

    The George Institute

    Adult participants with advanced unresectable or metastatic soft-tissue sarcoma.

    phase 2 small molecule active

    1 trial

  41. OPDIVO 10 mg/mL concentrate for solution for infusion., Relatlimab intravenous, 0.9% Sodium Chloride Injection, Avastin 25 mg/ml concentrate for solution for infusion.

    Bristol-Myers Squibb Australia Pty Ltd

    Advanced/metastatic hepatocellular carcinoma (HCC)

    phase 2 small molecule active

    1 trial

  42. OPDIVO 10 mg/mL concentrate for solution for infusion., Stivarga 40 mg film-coated tablets, anti-CTLA-4 NF Probody® mAb

    Bristol-Myers Squibb Australia Pty Ltd

    Advanced solid tumors (squamous cell carcinoma of the head and neck (SCCHN), non-small cell lung cancer (NSCLC), cutaneous melanoma, triple-negative breast cancer (TNBC), renal cell carcinoma (RCC), urothelial carcinoma, gastric, esophageal, cervical, and colorectal cancer (CRC)).

    phase 2 small molecule active

    1 trial

  43. OPDIVO 10 mg/mL concentrate for solution for infusion., YERVOY 5 mg/ml concentrate for solution for infusion

    Tour Hekla

    Unresectable locally advanced or metastatic urothelial cancer

    phase 2 small molecule active

    1 trial

  44. OPDIVO 10 mg/mL concentrate for solution for infusion., YERVOY 5 mg/ml concentrate for solution for infusion

    Ningbo Cancer Hospital

    NEOREM: Localized solid malignancies that are eligible to receive neo-adjuvant therapy and have medical unmet needs related to disease-free survival, overall survival or quality of life / NEO-1: Resectable stage III cutaneous or mucosal melanoma amenable to intratumoral neo-adjuvant immunotherapy.

    phase 2 small molecule active

    1 trial

  45. OPM-101

    Chongqing Precision Biotech Co., Ltd

    Advanced Melanoma

    phase 2 small molecule active

    1 trial

  46. ORIC-114

    Topiloric/Uriadec

    Solid Tumors

    phase 2 small molecule active

    1 trial

  47. ORIC-114

    Topiloric/Uriadec

    Solid Tumors

    phase 2 small molecule active

    1 trial

  48. ORSERDU 86 mg film-coated tablets, ABEMACICLIB, ABEMACICLIB, ORSERDU 345 mg film-coated tablets, ABEMACICLIB

    Stemline Therapeutics B.V.

    Brain Metastasis from Estrogen Receptor Positive, HER-2 Negative Breast Cancer

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many oncology Phase II programs exist?

2,640 programs match both the therapeutic area and stage filters in our published index.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.